Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Autor: Kater, A.P., Oers, M.H.J. van, Norden, Y. van, Straten, L. van der, Driessen, J., Posthuma, W.F.M., Schipperus, M., Chamuleau, M.E.D., Nijland, M., Doorduijn, J.K., Gelder, M. van, Hoogendoorn, M., Croon, F. de, Wittebol, S., Kerst, J.M., Marijt, E.W.A., Raymakers, R.A.P., Schaafsma, M.R., Dobber, J.A., Kersting, S., Levin, M.D., HOVON CLL Study Grp

Publikováno v: Haematologica-the Hematology Journal, 104(1), 147-154. Ferrata Storti Foundation
Haematologica, 104(1), 147-154. Ferrata Storti Foundation
Haematologica
Haematologica, 104(1), 147. Ferrata Storti Foundation
Haematologica, 104(1), 147-154
Kater, A P, van Oers, M H J, van Norden, Y, van der Straten, L, Driessen, J, Posthuma, W F M, Schipperus, M, Chamuleau, M E D, Nijland, M, Doorduijn, J K, van Gelder, M, Hoogendoorn, M, de Croon, F, Wittebol, S, Kerst, J M, Marijt, E W A, Raymakers, R A P, Schaafsma, M R, Dobber, J A, Kersting, S, Levin, M-D & HOVON CLL study group 2019, ' Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia ', Haematologica, vol. 104, no. 1, pp. 147-154 . https://doi.org/10.3324/haematol.2018.193854
Haematologica, 104(1), 147-154. FERRATA STORTI FOUNDATION

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a2ba6de52051a80de5f28c2c09d86ef
https://cris.maastrichtuniversity.nl/en/publications/0da833c7-95f9-4e2b-a612-f98da88c70bd

Alpha1-Antichymotrypsin Present in Therapeutic C1-Inhibitor Products Competes with Selectin - Sialyl Lewis(X) Interaction

Autor: Engel, R., Nunez, L.D., Roem, D., Mierlo, G. van, Holst, S., Oers, M.H.J. van, Wuhrer, M., Wouters, D., Zeerleder, S.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::af9e57d7b0d890eb310ed8ec9df027c7
https://hdl.handle.net/1887/99492

Identification of pathways involved in B-cell receptor-induced and FAS-induced B cell death

Autor: Lens, S.M.A., Drijver, B.F.A. den, Tesselaar, K., Oers, M.H.J. van, Lier, R.A.W. van

Publikováno v: Immunology Letters; 1997, Vol. 56 Issue: 1 p343-344, 2p

Transfusion associated complications in cardiac surgery : the swan song of the allogeneic leukocytes ?

Autor: Bilgin, M.Y.

Publikováno v: None

In the Netherlands 1 of 1.000 inhibitants undergo cardiac surgery annually. To compensate blood loss these patients receive often blood transfusions, which can cause unexpected adverse reactions. Allogeneic leukocytes may play a prominent role in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6aa1c328033d20ab5a03e5ba2a566c2f
https://hdl.handle.net/1887/17880